United States

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

7 Dec 2016
Change (% chg)

$-0.10 (-5.15%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for OREX.OQ


Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management... (more)


Beta: 3.00
Market Cap(Mil.): $28.30
Shares Outstanding(Mil.): 14.59
Dividend: --
Yield (%): --


  OREX.OQ Industry Sector
P/E (TTM): -- 42.12 30.77
EPS (TTM): -3.19 -- --
ROI: -6.96 -0.81 15.23
ROE: -29.62 -1.52 16.56

BRIEF-Orexigen signs commercialization, distributorship agreement with Valeant for Vontrave in Australia, New Zealand

* Orexigen Therapeutics Inc - Orexigen expects Valeant to file for regulatory approvals in both countries in first half of 2017

Nov 08 2016

BRIEF-Orexigen Therapeutics announces Q2 loss per share $1.73

* Orexigen Therapeutics reports business and financial results for the second quarter ended June 30, 2016

Aug 04 2016

BRIEF-Orexigen Therapeutics unit, ROVI announce agreement

* "Expect mysimba to contribute to group's revenue in next few years"

Aug 01 2016

BRIEF-Orexigen Therapeutics to release Q2 results on Aug 4

* Orexigen therapeutics to provide business update and discuss second quarter 2016 financial results on august 4, 2016 Source text for Eikon: Further company coverage:

Jul 21 2016

BRIEF-Orexigen Therapeutics announces a 1-for-10 reverse stock split

* Orexigen therapeutics announces stockholder approval of all proposals at 2016 annual meeting and reverse stock split

Jul 08 2016

BRIEF-Orexigen Therapeutics promotes Tom Cannell to COO, Jason Keyes to CFO

* Orexigen Therapeutics announces promotions of Tom Cannell to COO and Jason Keyes to CFO Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 08 2016

Earnings vs. Estimates